C21 Investments to Report Second Quarter Financial Results on November 11, 2025November 07, 2025 7:00 AM EST | Source: C21 Investments Inc.Vancouver, British Columbia--(Newsfile Corp. - November 7, 2025) - C21 Investments Inc. (CSE: CXXI) (OTCQX: CXXIF) ("C21" or the "Company"), a vertically integrated cannabis company, today announced it will release its financial results for the second quarter ended September 30, 2025, on Tuesday, November 11, 2025, before market open.For further inquiries, ...

It has been more than two weeks since gold prices notched record highs, but the debasement trade that has played a key role in the precious metal's rally this year is alive and well. ...

The trade wars have died down, but they have not disappeared — and that has left a cloud over the U.S. economy that's unlikely to go away soon. ...

ROLLING MEADOWS, Ill., Nov. 07, 2025 (GLOBE NEWSWIRE) -- RYTHM, Inc. (Nasdaq: RYM) (“RYTHM” or the “Company”) (formerly known as Agrify Corporation), which delivers well-being to consumers through its portfolio of iconic licensed brands and hemp-derived THC products including Señorita THC Margaritas and RYTHM, today announced financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Results Revenue from continuing operations of $4.0 million, up 98% from $2.0 million in the p ...

TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Evergold Corp. (TSX-V: EVER, WKN: A2PTHZ) (“Evergold” or the “Company”) is pleased to announce that it has closed its non-brokered private placement of an unsecured convertible debenture (the “Convertible Debenture”) for aggregate gross proceeds of $350,000 (“Offering”). The Convertible Debenture bears interest at a rate of 7.5% per annum and will mature on November 6, 2027 (the “Maturity Date”). Subject to certain conditions, the principal amount of the Convertibl ...

TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce its financial and operational results for the third quarter ending September 30, 2025. The Company remains in a strong financial position. A quarter-over-quarter comparison of Q3 2025 with Q2 2025 highlights a period of significant strengthening, with a 275% increase in shareholder equity, an 86% reduction in the debt-to-equity ratio, a 50% d ...

Data from studies conducted by investigators at the National Cancer Institute at NCI laboratories, part of a multi-year research effort, will be presented at SITCDover, DE, Nov. 07, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) (“AlphaTON”) and its wholly owned oncology subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (“Cyncado”), today announced a poster presentation at the Society for Immunotherapy of Cancer Annual Meeting, taking place November 5 to 9, 2025, in Nation ...

Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH Digital pathology reinforces fibrosis improvements observed through conventional pathology in the 96-week Phase 2b HARMONY trial SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transfor ...

­November 7, 2025 - TheNewswire - TORONTO, ON – Star Royalties Ltd. (“Star Royalties”, or the “Company”) (TSXV: STRR, OTCQX: STRFF) is pleased to highlight an update by Minera Alamos Inc. (“Minera Alamos”) (TSXV: MAI, OTCQX: MAIFF) on the development progress and exploration potential of its Copperstone Gold Mine (“Copperstone”). Minera Alamos is currently preparing an updated technical study to support Copperstone’s restart, following anticipated approvals of final amendments to its Mine Plan of Operation ...

MIRAMAR, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, announced today the data presented for their tetra-valent, second-generation T-Cell Engager (“TCE”) Program based on their novel TRBC platform technology, at the SITC 40th Annual Meeting, taking pl ...